Teleflex Incorporated
155 S. Limerick Road
Limerick
Pennslyvania
19468
United States
Tel: 610-948-5100
Fax: 610-948-0811
Website: http://www.teleflex.com
481 articles about Teleflex Incorporated
-
Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference
2/20/2024
Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET).
-
Teleflex Announces Extension of Arrow™ ErgoPack™ Complete System to Hemodialysis and Large Bore Central Venous Catheters
8/21/2023
Teleflex Incorporated, a leading global provider of medical technologies, announced the release of the Arrow™ ErgoPack™ Complete Kits with Hemodialysis and Large Bore catheters in the United States.
-
Teleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook
8/3/2023
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended July 2, 2023.
-
Teleflex Announces Quarterly Dividend - August 3, 2023
8/3/2023
Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
-
Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures
8/1/2023
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+ ™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy.
-
Teleflex Announces Second Quarter 2023 Earnings Conference Call Information
7/20/2023
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 3, 2023.
-
Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study
7/19/2023
Teleflex Incorporated today announced the completion of patient enrollment in the prospective multicenter Ringer TM PTCA study.
-
Teleflex Receives FDA Clearance for the Wattson® Temporary Pacing Guidewire
6/7/2023
Teleflex Incorporated today announced it will feature the Wattson ® Temporary Pacing Guidewire – the first commercially available bipolar temporary pacing guidewire designed specifically for use during TAVR and BAV – at TVT: The Structural Heart Summit, June 7-10 at the Phoenix Convention Center-West.
-
Teleflex Announces the Arrow® EZ-IO® Needle Is Now FDA Cleared For Use in an MRI EnvironmentFirst and Only IO Needle with MR Conditional Safety Status Labeling
6/6/2023
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, today announced that the Arrow ® EZ-IO ® Needle is the first and only Intraosseous (IO) Needle to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MR Conditional labeling.
-
Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
5/4/2023
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023.
-
Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States
5/2/2023
Teleflex Incorporated today announced the launch of two new devices designed to enhance PICC insertion procedures and reduce the chance of complications.
-
Teleflex Announces First Quarter 2023 Earnings Conference Call Information
4/20/2023
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 4, 2023.
-
Teleflex to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual
3/7/2023
Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 12:00 p.m. (ET).
-
Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results
2/23/2023
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2022.
-
Teleflex Announces Quarterly Dividend - February 23, 2023
2/23/2023
Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
-
Teleflex Expands Interventional Cardiology Portfolio with Two New FDA-Cleared Catheter Devices for Use in Complex Percutaneous Coronary Interventions (PCI)
2/22/2023
Teleflex Incorporated, a leading global provider of medical technologies, announced key milestones in the release of two new catheters: the U.S. Food and Drug Administration 510 clearance of the Triumph™ Catheter, and the first clinical use of GuideLiner® Coast™ Catheter.
-
Teleflex Announces Fourth Quarter 2022 Earnings Conference Call Information
2/9/2023
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 23, 2023. Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 23, 2023.
-
Standard Bariatrics, Inc., now part of Teleflex, Awarded Bariatric Stapling Technology Agreement with Premier Inc.
2/7/2023
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded a group purchasing organization (GPO) agreement with Premier ® , Inc. for the Titan SGS ® powered stapling device, expanding access to this innovative technology for surgeons affiliated with Premier.
-
Teleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift® System
12/15/2022
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that 400,000 patients have now been treated with the UroLift ® System, 1 a safe, effective and minimally invasive treatment option for benign prostatic hyperplasia (BPH), or enlarged prostate.
-
Teleflex Earns Top Spot in MedReps Best Places to Work 2023 Ranking
11/21/2022
Teleflex Incorporated today has announced it was named a MedReps.com 2023 Best Places to Work, earning the Number 1 spot for large companies and making this the sixth consecutive year the company has been on the list.